encourag outcom solid organ preserv
transport initi outperform
initi coverag transmed outperform rate
pt repres sale estim
transmed develop first kind multi-organ ex-vivo normotherm
perfus preserv transport system organ system oc oc
present paradigm chang solid organ preserv transport space
potenti allow better transplant outcom better econom
also increas donor pool organ use transplant end-
stage diseas patient construct stanc name temper
acknowledg first inning technolog lot
need learn
organ avail donor organ heart lung liver kidney present life-
save option end-stag diseas patient howev signific demand/suppli
imbal solid organ transplant exist uno estim patient
transplant waitlist transplant actual perform us
moreov patient die us everi day wait transplant
static storag standard care organ preserv
transport conveni present physiolog advers condit
organ donor organ eventu get transplant
organ system oc util normotherm ex-vivo perfus provid
near-physiolog state donor organ maintain addit nutrient
ad therefor potenti improv organ assess viabil
transplant outcom inde lot learn need happen potenti
expand usabl donor organ current level expand
donor pool excit
pipelin transmed submit pma applic heart indic
panel meet expect next month similarli readout
liver trial expect later approv indic along
lung commerci indic open oc unit world-wide
asp repres multi-billion dollar opportun
larg tam backdrop oc use favor given geograph
concentr transplant center huge imbal supply/demand
solid organ model assum oc use transplant
repres enthusiasm potenti technolog
improv outcom temper earli stage technolog
year price histori
transmed base andov
manufactur market organ
system oc first multi-
system solid organ preserv
analyst certif import disclosur see disclosur
oc repres disrupt technolog could potenti
revolution solid organ preserv transport
potenti narrow gap demand
suppli donor organ could also expand pool
usabl solid organ standard process
continu commerci uptak lung
continu commerci uptak dcd heart ou
clinic trial liver heart complet enrol
oc liver trial readout
oc heart panel pma approv
oc heart dcd outcom result trial stoppag due ethic
concern control arm
liver outcom superior static cold storag
oc manufactur hiccup qualiti issu yield problemat
unforeseen issu crop affect organ viabil
month pt repres sale estim slight premium aggreg med-tech space
current trade forward p/
transmed conduct numer clinic trial variou solid organ preserv transplant suffic say final outcom
depend donor recipi characterist also transplant techniqu specif follow-up period
compani balanc requir properli conduct clinic trial new indic label expans
commerci alreadi approv indic
organ transplant market realli seen innov year normotherm ex-vivo perfus repres paradigm
chang suffic say way clinic trial design current leav room debat henc like tug war
current practic static cold storag vs clinic benefit normotherm ex-vivo perfus market risk center
continu exist practic
tabl content
tap dcd heart transplant
need donor organ signific
organ procur dead donor constitut lifesav option patient live
howev remain seriou imbal donor organ avail patient
transplant list uno estim solid organ
transplant us kidney account liver account
transplant howev patient organ wait list
patient die everi day wait list intern though pictur isnt
better uno estim organ transplant world-wide
kidney implant heart transplant whether brain death circulatori death
account world-wide organ transplant despit critic
urgent organ need us account heart transplant world-wide
global statist patient wait list unclear suffic say
probabl million patient could benefit organ transplant
standard care donor organ procur transport static cold storag
static cold storag involv use special solut lower organ temperatur
level metabol requir greatli reduc organ
transport readi transplant case static cold storag may simpli
involv put solid organ contain full ice ship via airplan
anoth locat complic maze local organ procur alloc polici
add anoth bureaucrat layer patient navig lack
standard procur time organ viabil assess final transplant
led situat final solid organ realli get util
number donor organ call extend criteria condit normal
clinician wouldnt use organ transplant due comorbid thrown
away static cold storag provid benefit significantli lower metabol demand
solid organ lower temperatur therefor sustain organ howev
counterbalanc forc ischem time organ go therefor
limit durat organ function viabil reason donor
heart lung remain viabl hr liver hr
kidney hr geograph locat donor match
first multi-platform ex-vivo normotherm perfus system allow solid
organ preserv ex-vivo somewhat physiolog state use donor
blood pair perfus solut compos steroid vitamin drug etc
moreov ex-vivo normotherm perfus might repres fine balanc
keep organ perfus therefor reduc ischemia manag metabol
note pleas see initi report outperform cardiovascular
earli clinic evid oc encourag
earli clinic evid oc especi consid complex space
quit encourag oc lung trial design show non-inferior
surviv primari graft dysfunct grade within hour transplant
compar normotherm ex-vivo perfus use oc static cold storag outcom
inspir trial compar oc use normotherm perfus static cold storag
show oc better static cold storag fact superior primari
endpoint trial basi approv lung indic us may
next lung trial oc lung expand trial demonstr use oc lung
type organ current transplant result util
dcd util rate similarli oc heart proceed ii trial compar oc
static cold storag heart demonstr oc met primari effect
endpoint analysi popul exhibit greater surviv rate day
post-transplant trial also met secondari endpoint cardiac-graft relat
sae statist signific differ rel control arm
demonstr signific reduct injuri ischem time donor heart compar
cold storag control oc current evalu oc heart expand
studi could basi heart indic approv us sometim later
final liver key indic oc final result oc liver
european reviv trial demonstr oc liver result approxim
util dcd donor liver oc liver trial readout us expect
occur sometim posit outcom trial could lead anoth
case new technolog disrupt statu quo inher
complac inertia overcom given long-establish practic good bad
case normotherm ex-vivo perfus oc note use cold
storag realli way adequ measur organ viabil sometim one
wait transplant determin success static cold storag
exampl reduc cell metabol need lower temperatur increas
ischem time net effect sometim deleteri especi organ
heart time essenc oc hand allow
normotherm perfus therefor reduc ischem time maintain metabol
rate preliminari evid lung heart seem suggest strategi
better outcom howev would remiss highlight still
learn curv ahead clinic trial streamlin valu proposit oc
exampl perfus mix decid perfus algorithm titrat
particular organ includ pressur durat etc organ viabil assess
european accept oc dcd heart indic contend
time best practic algorithm per solid organ emerg reshap organ
preserv transplant space
transmed first inning disrupt technolog solid organ
preserv transport space abil expand potenti donor pool use
extend criteria organ tradit unus organ function assess
case improv outcom compar repres view uniqu
valu proposit everi year world-wide patient organ transplant
wait list die shortag accept donor organ larg blame oc
view present one opportun close gap demand suppli donor
organ improv outcom inde compani earli stage
paradigm shift technolog view within context view
clinic trial go definit conclus everi time especi given
heterogen donor recipi local organ procur
transport process techniqu transplant extent extern
variabl normal believ oc could present signific step chang
outcom pro forma model assum rel mute unit estim solid organ
transplant within us ou upcom clinic trial readout could
drastic chang trajectori oc adopt believ prudent
conserv stage pt repres sale premium
aggreg med-tech univers trade forward sale per factset
estim henc outperform rate
transmed manufactur organ system oc portabl organ perfus
optim monitor system util proprietari custom technolog
replic near-physiolog condit donor organ outsid human bodi
organ system includ oc lung portabl perfus ventil monitor
system maintain organ near-physiolog state allow physician assess
improv condit lung donor recipi site oc
approv lung indic us heart lung liver indic ou
compani conduct numer clinic trial variou indic readout
expect occur next month potenti open signific new
transmed oc portabl organ perfus ventil monitor medic
devic indic preserv standard criteria donor lung near physiolog
ventil perfus state doubl lung transplant oc lung system
first commerci product us although heart lung liver version
approv europ oc system custom organ compos
oc consol highli portabl electromechan devic hous control
function oc design fit current workflow organ
transplant oc technolog platform fundament equip
proprietari pulsatil blood pump simul beat heart perfus organ outsid
bodi proprietari softwar control titanium blood warmer maintain blood bodi
temperatur maxim portabl ga exchang maintain concentr
custom hemodynam sensor monitor assess organ function outsid
bodi software-control miniatur electromechan system univers power
suppli hot-swapp batteri maxim portabl travel distanc organ
retriev proprietari wireless monitor control softwar custom carbon fiber
oc consol structur reduc overal weight system maxim portabl
oc perfus set steril biocompat single-us dispos set store
organ circul blood oc perfus set
includ accessori need place organ system oc solut
set nutrient-enrich solut use blood replenish deplet nutrient
need optim organ condit outsid human bodi solut may
includ energy-rich perfus nutrient well suppli therapeut vasodil
endotheli stabil and/or preserv reduc edema provid endotheli
support organ compon may includ dextran nacl kcl magnesium
methylprednisolon equival cefazolin ciprofloxacin voriconazol solut
mix whole blood pack red blood cell form oc lung perfus solut
solut provid compon maintain function respir
viabl lung ex-vivo near physiolog condit
exhibit order transmed individu compon lung oc
exhibit circuit diagram transmed oc heart oc lung system
potenti benefit transmed oc
oc perfus modul design maintain organ deem
suitabl transplant exampl case donor heart organ
reanim outsid donor bodi continu assess use aortic pressur
coronari flow differenti lactat profil arteri venou lactat sampl
least everi hour stabil flow manipul aortic pressur thu
system abl provid organ assess use combin lactat level
perfus pressur fraction donor organ thought viabl
transplant part due poor techniqu organ assess use hypotherm
storag transport method exampl donor heart uk
donor heart us get transplant lung liver statist even wors
reduct ischem time
appar benefit normotherm donor heart perfus transport
reduct cold ischem time numer case studi report
donor organ success transplant use normotherm perfus system
beyond normal ex-vivo shelf life use hypotherm method potenti
doubl benefitit could allow use organ geograph wider area
time prevent organ procur transplant team high speed retriev
deliveri logist accord ishlt intern societi heart lung
transplant registri mortal heart transplant
lead caus death attribut primari graft failur donor age length
ischem time heart strong predictor graft failur ishlt registri
reveal risk primari graft failur heart transplant exampl begin
increas ischem time exce hour present signific logist
econom clinic challeng transplant team use oc least base
anecdot evid allow push total ex-vivo time without
ischemia therefor allow potenti better transplant better outcom
critic applic oc expand potenti donor patient pool
especi circulatori death patient dcd number circulatori death due
patient drug overdos sourc http //www healthleadersmedia com/clinical-
care/fatal-opioid-overdoses-provide-favorable-organ-donor turn suffer
hepc remain consider excit role oc dcd organ
confess still remain somewhat gray area assess
noth perform oc titrat perfus algorithm
content perfus reflect fact
standard assess criteria variou organ besid visual check
possibl monitor mechan lactat enzym isnt
uniform criteria organ assess logic would dictat normotherm
perfus condit reduct total ischemia time physiolog mimick
condit lead better outcom current transplant industri
develop rigor valid criteria absenc oc offer best chanc
organ surviv
abl properli triangul calcul transmed given
complex logist polit econom social challeng involv organ
procur assess transplant way verifi
exact estim highlight underneath henc simpli paraphras
transmed highlight suffic say still substanti
whether number accur even thousand extra donor organ
enabl oc impli revenu opportun transmed hundr
million dollar rang
transmed estim current donor lung util annual
transplant key geographi result approxim organ
compris potenti donor potenti dcd donor
go unutil year transmed oc lung expand trial demonstr
use oc lung type organ current transplant result
util dcd util rate impli total potenti
address opportun approxim annual approxim
util donor remain approxim repres util
exhibit estim address lung opportun ocsu canada eu australia
transmed estim current donor heart util annual
transplant key geographi result approxim organ
compris potenti donor potenti dcd donor
go unutil year appli util rate donor heart
util rate dcd donor heart impli total address opportun
approxim annual approxim repres current
transplant heart approxim repres improv util
donor remain approxim repres util dcd donor
exhibit estim address heart opportun ocsu canada eu australia
transmed estim current donor liver util annual
transplant key geographi result approxim organ
compris potenti donor potenti dcd donor
go unutil year final result oc liver european reviv trial
demonstr oc liver result approxim util
dcd donor liver appli util rate impli total potenti address
opportun approxim annual approxim repres
current transplant liver approxim repres improv util
donor remain approxim repres util dcd donor
exhibit estim address liver opportun ocsu canada eu australia
unit network organ share uno privat non-profit organ
manag nation organ transplant system contract feder
govern bring togeth hundr transplant organ procur
profession thousand volunt uniqu collabor help make life-
save organ transplant possibl day system serv model
transplant system around world uno involv mani aspect organ
transplant donat manag nation transplant wait list match
donor recipi hour day day year maintain databas
contain organ transplant data everi transplant event occur
bring togeth transplant commun develop polici make best use
limit suppli organ give patient fair chanc receiv organ
need regardless age sex ethnic religion lifestyl financial/soci statu
monitor everi organ match ensur organ alloc polici follow
provid assist patient famili member friend educ transplant
profession import role donat transplant process
educ public import organ donat organ transplant
polici key organ highlight
guidelin heart transplant revamp sever year heart
candid group accord three status urgent
somewhat urgent least urgent specif criteria updat reflect patient
current health care get begin octob candid
list accord six medic urgenc status statu urgent statu
least urgent highli detail criteria statu assign sever
basic factor consid
patient one advanc support therapi ecmo
artifici heart and/or patient difficulti control life- threaten
condit ventricular arrhythmia tachycardia fibril get
current treatment complic infect clot and/or
treatment requir stay hospit gener patient higher
statu complic leav hospit
statu deem urgent need heart transplant result
statu patient consid first heart offer wider geograph area
mile donor locat candid statu
patient statu may chang symptom get better wors treatment chang
one critic gate factor due dilig call heart transplant
requir surviv rate donor heart uno criteria limit
accept donor heart perceiv surviv
understand longer enforc stringent criteria remain
seen uno follow suit relax criteria would
explain us open potenti patient pool donor heart
organ procur transplant network implement new
liver intestin organ distribut system improv process match life-
save organ candid greatest need new polici expect save
live annual provid transplant access urgent candid
also expect increas number pediatr liver transplant new system
replac use decades-old geograph boundari donat servic area
dsa transplant region emphas medic urgenc liver transplant
candid distanc donor hospit transplant hospit
accord new polici went effect februari liver
deceas donor first offer urgent liver transplant candid statu
list transplant hospit within radiu nautic mile donor
hospit follow offer urgent candid liver adult donor
offer candid hospit within distanc nautic mile
donor hospit offer group medic urgenc polici
develop transplant donat expert recipi donor famili around
countri consider public comment new polici take
effect time sustain increas organ donat transplant unit
state nearli total transplant perform nationwid set
annual record seventh year row total liver transplant
perform involv deceas donor increas total
decemb approv new system match kidney pancrea
transplant candid organ deceas organ donor new polici
establish new distribut area base donor locat project
increas equiti transplant access candid regardless live list
transplant newli approv system kidney pancrea offer except
rare well-match donor recipi combin nationwid offer first
candid list transplant hospit within nautic mile donor hospit
offer accept candid made candid beyond
nautic mile distanc candid also receiv proxim point base
distanc transplant program donor hospit proxim point
intend improv effici organ placement ad prioriti candid
closer donor hospit candid within initi nautic mile radiu
receiv maximum two proxim point outsid initi circl receiv
maximum four proxim point point assign highest closest
donor hospit decreas distanc increas new system
replac three-tier approach use sinc begin nation organ alloc
polici current kidney pancrea offer go first
candid list hospit within donat servic area dsa
donor hospit locat dsa reflect assign servic area organ
procur organ opo dsa fix often irregular geograph
boundari set express purpos optim organ alloc
instanc portion dsa contigu mean local
donor match may travel servic area belong opo organ offer
accept dsa level current made candid hospit within
region donor hospit final offer accept dsa
region level made candid list transplant program anywher els
 lung alloc polici priorit lung transplant candid lung offer
assign lung alloc score score la use priorit wait list
candid base combin waitlist urgenc post-transpl surviv
context waitlist urgenc defin expect happen candid given
characterist next year doesnt receiv transplant post-
transplant surviv defin expect happen candid given
characterist first year transplant receiv
transplant la calcul involv follow step calcul wait list
surviv probabl next year calcul waitlist urgenc measur
calcul post-transpl surviv probabl first post-transpl year
calcul post-transpl surviv measur calcul raw alloc score
normal raw alloc score obtain la
girlanda et al world journal transplant volume etc
avail donor organ deceas patient made organ transplant
realiti pave way improv qualiti life recipi howev shortag
viabl organ remain major obstacl organ transplant world-wide us
patient transplant wait list actual transplant
expect occur sourc www organdonor gov/statist patient
us die everi year wait suitabl transplant scarciti donor organ
lead situat patient wait list chanc die
wait organ becom avail shortag organ global scale
also show similar trend world organ sever intern
agenc taken sever initi address shortag
exhibit order trend donor organ avail actual transplant us transplant perform
organ us wait list us
exhibit order trend world-wide transplant transplant per patient heart kidney constitut
transplant
global observatori donat transplant world organ statist
observ previou exhibit
approxim organ transplant world-wide
us constitut world-wide transplant
kidney sought organ transplant
state otherwis kidney account organ transplant
donat
liver constitut second largest categori account
transplant moreov liver donat live donor
heart transplant whether brain death circulatori death account
world-wide organ transplant despit critic
urgent organ need obvious heart donat deceas
patient us account heart transplant world-wide
spain lead world term live total donor organ per patient
global statist patient wait list avail us howev
suffic say probabl million patient could benefit
uno conduct deceas donor potenti studi us determin
potenti donor pool meet basic criteria
donat actual donat rate consider lower age group
year vs patient year group
exhibit approx donat rate us group
girlanda et al world journal transplant
donat brain death
vast major organ procur us death neurolog criteria
lack corneal reflex cough reflex facial motor respons pain stimuli
pupillari respons light etc brain death determin irrevers cessat
brain stem activ document bedsid neurolog test oxygen comatos
person suffer devast irrevers brain injuri fulfil criteria brain
death maintain mechan ventil cardio-circulatori activ organ
perfus support need inotrop condit
exhibit approx procur donor organ
girlanda et al would journal transplant
brain-dead patient ideal donor sourc heart ideal warm
ischemia influenc time organ must harvest declar
death howev brain death undesir outcom intens care medicin
result abil prolong distort process die patient acut
sever cerebr damag avail brain-dead donor highli suscept
chang differ caus countri regul time period mani
countri brain-dead patient becom rare outcom intens care
actual number declin import reason declin
incid mortal subarachnoid hemorrhag traumat brain injuri
donat circulatori death dcd
unlik organ donor circulatori death dcd account rel
much smaller portion total organ procur us global scenario
patient suffer sever brain injuri fulfil criteria brain death
may still organ donor patient advanc direct patient famili
decid withdraw life support circumst consent organ donat
obtain patient brought oper room ventil
disconnect life-sustain medic withdrawn cessat
cardiocirculatori activ minut depend local protocol patient
pronounc dead member primari team declar death organ
procur team arriv oper room begin organ recoveri
dynam involv dcd pathway differ beyond scope
report specif highlight issu post-organ procur
transmed fit within paradigm
system chang brain death
sinc organ procur transplant brain death focu
critic paramet organ manag ultim influenc organ viabil
graft uptak shown time frame organ recoveri transplant
vari depend type organ manag protocol
exhibit time frame organ recoveri transplant process
brain death induc consider hemodynam hormon metabol chang
left untreat may result cardiac arrest somat death earli aggress
hemodynam manag hormon support may delay temporarili revers
event hemodynam instabl metabol derang
brain death induc sequenti system physiolog chang ischemia propag
cerebrum spinal cord ischemia progress downward distal
medulla oblongata sympathet storm unleash complet herniat
ischemia spinal cord follow gradual loss sympathet henc
vascular tone lead progress hypotens cardiovascular collaps cardiac
function reduc brain death great extent attribut
catecholamin cardiotox brought sympathet storm numer medic
journal articl sourc novitzki et al transplant novitzki et al annal
thorac surgeri seben et al european journal cardiothorac surgeri
szabo et al transplant etc shown explos induct
brain death lead greater sympathet storm also rapid
subsequ loss sympathet tone vasodil occur loss sympathet
tone afterload reduct result reduc coronari perfus pressur rel
intravascular hypovolemia consequ decreas preload alter load
condit signific effect myocardi contractil myocardi injuri
trigger brain death larg extent may revers avoid restor
cardiac load condit hemodynam collaps brain death brain death
result reduc afterload due primari cardiac dysfunct
signific reduc coronari perfus cardiac perform set
settl brain death induc endotheli dysfunct impair endothelial-depend
vasodilatori mechan may thu contribut observ reduct coronari
lung usual often deem medic unsuit lung
multipl organ donor use transplant sourc venkateswaran et al
annal thorac surgeri although brain death initi numer morpholog
physiolog chang pulmonari dysfunct brain-dead organ donor often
associ incid relat brain death per se aspir pneumonia
contus ventilator-induc injuri brain-death induc lung injuri dysfunct
relat neurogen pulmonari edema inflammatori acut lung injuri
dont go detail report
addit sympathet activ rise catecholamin level brain death caus
signific chang endocrin function reflect anterior posterior pituitari failur
research endocrin level relat cortisol insulin triiodothyronin post
immunolog aspect brain death
brain death associ releas proinflammatori cytokin inflammatori
respons detect organ suitabl transplant lead
immunolog activ organ engraft result histolog damag
decreas function lower graft surviv compar organ live donor
increas blood level sever cytokin tnf-
seen sever cerebr injuri brain death up-regul
cytokin somat organ increas organ wherea tnf- seem
increas lung tissu heart tissu see signific increas mrna
origin cytokin though remain well understood sympathet storm
subsequ hemodynam instabl may lead hypoperfus ischemia variou
organ consequ activ cytokin system
implic organ manag brain death
potenti organ donor suffer intracrani hemorrhag traumat brain injuri
treatment aim save brain treatment often includ
heavi sedat infus hyperoncot solut high salin level reduc
intracrani pressur improv cerebr hemodynam heavi sedat offend
demand infus catecholamin restor cardiac output achiev certain
target perfus pressur goal alway reduc time brain death
organ procur maintain adequ circul blood volum proper
cardiac output perfus pressur assum optim deliveri tissu
depend degre hemodynam instabl donor might need fluid
resuscit inotrop support vasopressor hormon substitut initi
hypotens may occur much donor sustain hypotens
associ impair graft function hypovolemia common fluid resuscit
usual consid first step correct hypotens howev hypervolemia may
aggrav rv dysfunct caus rapid deterior lung function goal
therefor usual achiev normovolemia thorac organ harvest
hand kidney function seem benefit aggress fluid regimen
make necessari balanc antagonist interest organ relat fluid
resuscit consensu kind fluid use
resuscit though adequ fluid resuscit often suffici restor blood
pressur cardiac output approx donor requir addit vasoact
inotrop vasopressor support high use catecholamin shown
induc myocardi damag similar chang induc sympathet storm
brain-death led number donor heart refus surgeon due
dose catecholamin use howev achiev adequ coronari perfus pressur
probabl import avoid high dose catecholamin
exhibit biolog process induc ischemia reperfus lead primari graft failur
key aspect organ manag adequ hemodynam monitor
icu immunosuppress strategi pulmonari care brain dead patient
administr methylprednisolon brain dead donor associ improv
short-term long-term outcom transplant organ variabl lung
transplant use methylprednisolon shown singl
import predictor graft surviv final lung-protect ventil strategi low
pressur tidal volum avoid ventilator-induc lung injuri recommend
ehtuish et al intechopen com bellini et al journal intern medic
research volume salehi et al yale journal biolog
optim graft preserv prior implant recipi bodi remain one
major challeng transplant surgeri primari graft function long-term
outcom depend ischemiareperfus injuri iri consider
parenchym damag occur preserv period retriev
implant evid differ organ differ resist threshold
ischem insult threshold could affect preserv modal
hypotherm machin perfus hmp normotherm machin perfus nmp
date remain common preserv modal simplic
lower cost despit grow evid higher risk subsequ transplant damag
literatur shown organ retriev extend criteria donor donor
cardiocirculatori death suscept iri compar standard donor
thu keep expand donor pool margin organ paramount tailor
preserv modal characterist individu graft
one size fit remain unclear temperatur set prefer
anoth optim organ preserv consensu optim
temperatur differ organ intrins characterist preserv
modal might tailor case-by-cas basi
exhibit metabol rate reduc decreas temperatur human
hypothermia organ preserv
origin rational cold preserv organ much like put food
refriger howev rational cool organ implant
base slow cell metabol thu reduc oxygen requir
ischem period outsid human bodi temperatur cell
metabol fall normal rate tissu burn energi
store far slowli requir less sustain activ
cool organ thought help delay onset ischemia condit organ
becom dysfunct damag due lack put organ ice also
stretch cell limit energi store prevent harm metabolit build
break organ tissu
yet evid gold standard temperatur human graft
hypotherm set slow cell metabol reduc demand oxygen
prevent chemic process caus ischem injuri
preserv period time organ need flush preserv
solut protect damag extrem cold bodi temperatur cell pump
chemic membran order maintain low concentr
sodium high concentr potassium within cell cell cold cant
pump effici chemic leak across membran time leaki cell
swell excess fluid sustain seriou damag preserv solut help delay
damag keep sodium potassium level check solut also contain
nutrient antioxid sustain cell subdu inflamm
exhibit comparison variou method organ preserv
normothermia organ preserv
basic principl normothermia organ preserv minim deleteri
effect ischemia anoxia organ outsid human bodi
hypotherm set slow cell metabol reduc demand oxygen
prevent chemic process caus ischem injuri
preserv period despit possibl deliv hypotherm machin
perfus use oxygen machin perfus demonstr clinic studi
normotherm perfus seem provid addit oxygen physiolog
platform repair margin organ deliv therapeut direct contact
organ blood suppli thu avoid complic associ system
kittleson et al jacc heart failur volume suzuki et al seminar
respiratori critic medicin volume nicoara et al american journal
primari graft dysfunct syndrom encompass spectrum mild sever organ
injuri occur within certain time-frame transplant differ organ
differ sensit pgd varieti factor predispos organ pgd
pgd lung transplant character acut lung injuri occur within first
hour lung transplant pulmonari edema diffus alveolar damag
clinic manifest progress hypoxemia radiograph pulmonari infiltr
without identifi caus pgd form acut respiratori distress
syndrom ard share characterist factor predispos ard
trauma sepsi pgd develop progress encompass spectrum
acut lung injuri milder dysfunct sever lung injuri standard
definit pgd base radiograph pulmonari infiltr p/f
ratio assess sever time point lung transplant ideal p/f ratio
measur posit end expiratori pressur peep cm
recent analysi lung recipi enrol prospect
cohort studi ten us lung transplant center lung transplant outcom group
ltog show incid grade pgd overal
incid grade pgd time point first hour sourc
diamond et al american journal respiratori critic medicin volume
incid grade pgd across center though vari
significantli reflect differ practic pattern differ risk factor
distribut across center sinc ishlt standard definit grade
incid sever pgd grade report
incid sever pgd grade time point first hour
report pgd signific impact earli morbid mortal
lung transplant result prolong length mechan ventil prolong
intens care unit icu hospit stay increas cost increas short-term
mortal studi demonstr better discrimin predict mortal
short-term grade pgd compar grade demonstr significantli
higher risk day mortal account all-caus mortal within
period studi hour grade pgd associ increas
day mortal absolut mortal increas risk persist year
post-transpl absolut mortal increas year furthermor grade
pgd strongli associ long-term mortal even condit year
surviv survivor grade pgd month also shown cover far
less distanc measur minut walk distanc without grade pgd
pgd heart transplant present sever ventricular dysfunct donor graft
fail meet circulatori requir recipi immedi post-
transplant period may manifest either singl biventricular dysfunct low
cardiac output hypotens despit adequ fill pressur pgd defin
separ entiti secondari graft dysfunct discern
caus allograft dysfunct identifi caus includ hyper-acut
reject graft dysfunct secondari pulmonari hypertens recogn
intraop complic diagnosi pgd made within hour post-
transplant separ pgd-lv pgd affect left ventricl
biventricular failur pgd-rv isol right ventricular involv sever
scale appli pgd-lv mild moder categori reli
requir inotrop support composit score mild moder
alongsid either use echocardiographi identifi ventricular dysfunct right heart
catheter demonstr hemodynam compromis echocardiographi
criteria lvef consid diagnost pgd absenc secondari
caus regard hemodynam paramet high fill pressur right atrial
pressur rap mmhg pulmonari capillari wedg pressur pcwp
mmhg indic pgd occur context low cardiac index ci
last least hour requir intra-aort balloon pump signifi moder
pgd-lv wherea requir extracorpor short-term mechan circulatori
support form extracorpor membran oxygen ecmo ventricular assist
devic vad form percutaneous/surg diagnost sever pgd-lv
pgd-rv sever scale diagnos base requir
right-sid short-term right heart cathet measur hemodynam
keep isol right-sid dysfunct rap mmhg pcwp mmhg ci
pgd one major complic liver transplant associ higher
morbid earli post-transpl period may compromis graft surviv pgd
relat ischemia reperfus injuri transplant organ may subdivid
earli allograft dysfunct ead primari non-funct pnf sever
manifest primari graft dysfunct occur liver transplant pnf
incid rang lack univers accept pgd definit
diagnost criteria wide variat risk factor describ literatur preclud
adopt standard procedur across organ transplant center variabl cut-
point employ ead definit diagnosi differ studi laboratori
chang reflect liver metabol function first day transplant
serum alanin aminotransferas alt aspart aminotransferas ast
level prothrombin time pt intern normal ratio inr serum lactat
ammonia level commonli use paramet earli allograft dysfunct
known associ lower graft patient surviv rate longer stay intens
care unit icu increas post-operative morbid mortal
organ transplant immunosuppress use prevent bodi either
recognit attack foreign organ via variou immun respons transplant
reject involv bodi produc cell immun respons recogn
marker foreign tissu call antigen treatment regimen use prevent reject
employ drug differ class take advantag complementari action
minim toxic drug choic depend organ transplant tailor
individu minim transplant-rel morbid type drug use
immunosuppress organ transplant calcineurin inhibitor cyclosporin
globulin basiliximab infliximab sirolimu deriv everolimu sirolimu
organ alloc polici intens polit huge dispar differ
region countri number avail donor organ amount
peopl await transplant south mid-west tend donor
recipi statesnot new york californiahav revers
situat given massiv cost involv set transplant program set
nation polici signific financi impact lucr transplant program
constitu hospit put immens pressur congression repres
outsid influenc therefor guarante recent polici chang uno
geographi base sick base criteria thrown wrench budget
number hospit
remov storag transport solid organ donor profoundli alter
hemostasi interior milieu organ effect manifest degre
return normal organ function delay prevent transplant
complet injuri organ sustain recoveri preserv
transplant occur primarili result ischemia hypothermia static cold
storag offer simpl way preserv transport organ current
commonli use method howev number limit associ
includ tissu damag induc prolong hypotherm preserv difficulti
assess donor organ function viabil inevit ischemia-reperfus injuri
limit opportun organ repair time util extend criteria
organ becom problemat lead unutil donor organ
moreov offer option organ repair regener sinc addit
compon preserv solut ad low temperatur
normotherm ex-vivo perfus open new door
aggress investig clinic trial world
ehtuish et al intechopen com altinor et al experiment clinic
organ donat transplant expens matter len look
gap demand suppli univers problem financi cost includ
transplant evalu test organ procur transplant surgeri recipi
post-operative medic care immunosuppress therapi relat
donat exampl one studi estim cost associ kidney
donat transplant live donor result cost healthcar
system also donor live kidney donor miss total work hour
unpaid result lost wage mean caregiv lost
wage mean although donor receiv financi assist
incur net financi loss period report loss exceed
burden greater farther distanc travel
transplant center lower household incom unpaid work hour miss
exhibit cost incur live kidney donor one studi
rodrigu et al american journal transplant volume
estim base mean wait time kidney transplant
month privat payer spend end-stag renal diseas care
first month medicar second insur spend nearli
addit month primari payer sourc formica et al american
journal transplant volume us direct cost dialysi exceed
per year per patient medicar system wherea privat payment
nearli doubl amount
turri associ arq gastroenterolog volume evalu total cost
patient wait list liver transplant main resourc relat higher
cost found patient wait list liver transplant subject mani
complic incurr led hospit procedur increas
cost conclud patient wait list cost liver transplant increas
patient sever increas studi japan kitazawa et al transplant
process volume analyz cost transplant report living-donor liver
transplant expens transplant procedur total cost nearli
cost deceased-donor renal transplant higher cost living-
donor renal transplant procedur versu versu
exhibit order approx waitlist mortal rate organ approx percent donor organ use average bill cost
last exhibit interest view simpli captur total billabl
cost relat particular organ donat transplant captur indirect
cost donor neither captur ancillari cost time
patient waitlist moreov cost vari consider depend countri
inspir studi random multi-cent intern prospect clinic trial
investig safeti effect oc lung system current cold storag
standard care soc preserv donor lung separ inclus exclus
criteria use donor recipi detail fda pma
trial basi pma approv march lung indic howev
confus trial implic oc system
view rudimentari natur way organ preserv cold storag lack
rigor clinic trial hypotherm storag make proper comparison
somewhat problemat highlight two compet factor
organ storag transport ischemia metabol rate
temperatur reduc metabol rate cellular level drastic
reduc refer cryopreserv effect exampl well
accept stroke therapi reduc bodi temperatur reduc cellular
energi requir therefor caus temporari dormanc intervent
carri problem though stroke therapi
hypothermia requir system natur caus patient freez
ischemia given organ bodi normal physiolog
condit key question reduc time ischemia organ
therefor potenti improv host graft accept long-term outcom
longer organ remain ischemia without cryopreserv
greater chanc host-graft dysfunct poor outcom
essenc use cold storag favor lower metabol rate take
account level ischemia organ suffer lead small percent
donat organ ultim transplant henc conceptu normotherm
perfus could strike delic balanc two devil alway
initi primari effect endpoint inspir trial composit patient
surviv post-transpl absenc hr post-transplant
primari endpoint later modifi within hr post-transplant
pgd primari graft dysfunct form acut lung injuri known seriou
complic lung transplant sever form shown
correl poor short-term long-term outcom includ reduc surviv
increas incid bronchiol obliteran syndrom
lung turn
turn flow set higher recommend user filter assembl oc reservoir donor lung turn
due clinic concern potenti air embol warm ischemia
stage digress discuss correl pgd lung surviv
key understand outcom depend definit pgd highlight one
larg studi evalu lung transplant outcom us span
sourc christi et al american journal respiratori critic medicin volume
author evalu long-term outcom subject primari graft
dysfunct pgd defin ratio less beyond hour
transplant evid radiograph infiltr absenc secondari
caus allograft dysfunct data collect patient outcom
assess moreov assess potenti bia effect earli mortal subject
surviv least one year also analyz long-term surviv pgd main
find studi
overal incid primari graft dysfunct incid
vari year period observ
all-caus mortal day primari graft dysfunct versu
patient without graft dysfunct
among subject die day primari graft dysfunct
among patient surviv least year primari graft
dysfunct significantli wors surviv ensu year
relationship pgd mortal among one-year survivor strike
rel increas risk mortal next four year although
etiolog find uncertain plausibl explan includ
influenc episod prolong critic ill survivor pgd well
potenti increas immunogen allograft earlier sever
exhibit overal surviv patient pgd without pgd overal surviv patient surviv least
one year caus death
christi et al american journal respiratori critic medicin volume
come back inspir trial protocol allow donor lung perfus
oc lung devic either oc lung solut commerci low potassium dextran
lpd solut supplement pack red blood cell addit compar
outcom transplant perform oc result includ subgroup
analysi transplant also use oc solut view use
lpd solut definit yield confound includ
protocol henc overal data present trial focu simpli
oc solut arm basi pma approv oc lung
indic forest plot show amend primari effect endpoint
oc solut group assess result actual product market
oc solut subgroup oc met non-inferior test analys
statist superior control arm pp popul
exhibit amend primari effect endpoint oc solut group reduct within hr
single-arm pivot trial done eight institut across usa germani
belgium lung extended-criteria donor includ fulfil one
follow criteria ratio donor lung mm hg less expect
ischem time longer hr donor age year older lung donor
circulatori death recruit assess use oc lung lung
transplant show stabil oc lung variabl
mm hg accept transplant surgeon patient adult
bilater lung transplant recipi primari efficaci endpoint composit
patient surviv day post-transpl absenc within hour post-
transplant pre-specified object perform goal object
oc lung expand trial demonstr abil oc lung improv
donor lung util current unutil dcd donor demonstr
reason assur effect safeti trial inclus criteria focus
current unutil dcd donor lung enrol lung transplant recipi
donor lung would otherwis unutil donor lung use
oc lung expand trial declin transplant averag time
transplant center reach center particip oc lung expand
trial expand studi miss opc criteria key clinic driver
miss primari endpoint rate within initi period
post-transplant due challeng natur donor lung criteria includ
trial howev patient surviv day post-transplant primari
endpoint oc lung expand trial establish prior initi studi
base publish data avail within initi
period post-transplant reflect data current util donor lung
although analysi head-to-head comparison thu definit
evid efficaci oc lung result significantli lower rate within
initi period post-transplant compar similar donor cohort
exhibit order percent lung use expand studi compar analysi surviv
proceed ii first trial machin perfus technolog solid organ
transplant use oc system admittedli first kind trial therefor
trial design could potenti somewhat flaw given lack proper goalpost put
context one-year surviv post heart transplant htx
condit half-lif time patient surviv first
year still aliv yr uno report number stood
year sourc ishlt registri updat howev number
one year margin improv last three decad possibl caus
dispar may includ difficulti detect treat factor cardiac
allograft vasculopathi malign affect long-term mortal
exhibit order one-year surviv htx condit half-lif htx yr current challeng htx
proceed ii trial open-label random multi-cent trial demonstr
non-inferior oc heart transplant system cold storag current heart
transplant market approxim patient enrol us intern
center primari endpoint surviv post-transplant graft
surviv non-inferior margin analys done pp as-
treat popul june sept patient
randomli assign organ system group standard cold storag
group thirty-day patient graft surviv rate oc
group standard cold storag group eight patient
oc group nine patient standard cold storag group cardiac-
relat sae outcom proceed ii studi shown summari result
oc heart proceed ii trial includ oc met primari effect
endpoint analysi popul demonstr greater surviv rate day
post-transplant surviv rate statist differ
control arm trial met secondari endpoint cardiac-graft relat sae
statist signific differ rel control arm demonstr signific
reduct injuri ischem time donor heart compar cold storag control
post-hoc observ analysi all-caus mortal month post-
transplant graft-rel death oc group similar number
standard care group overal death higher oc group
exhibit outcom oc proceed ii trial
note debat five standard criteria donor heart random
oc group deem non-viabl due high lactat ultim
transplant heart includ final analysi remain point
content sourc freed et al lancet proceed ii help transmed
identifi sever trial design devic improv led modifi design
oc heart design oc heart expand trial understand
oc system refin optim perfus ad complianc
ao root optim coronari fill time new aorta cannula design iv
infus pump regul aop base set target user result compani
voluntarili withdrew origin pma applic oc heart prior approv
effort expand data includ oc heart expand trial result well
supplement proceed ii result long-term follow-up data collect
part origin trial protocol
oc heart expand single-arm multi-cent trial evalu oc expand
criteria heart object trial demonstr abil oc
heart improv donor heart util current unutil donor
demonstr reason assur effect safeti requir pma approv
indic trial inclus criteria focus current unutil donor
heart enrol heart transplant recipi donor heart would otherwis
unutil donor data obtain uno demonstr us
donor heart use oc heart expand trial declin transplant
averag time transplant center reach center particip
oc heart expand trial due varieti clinic logist reason includ
donor organ qualiti donor age expect injuri ischem time travel distanc
type donor total patient pool patient indic
expand criteriaischem time hr lvh minut older yr
coronari arteri diseas lvef result expand trial show
use oc heart result success util donor heart
reject transplant transplant center use cold storag
despit higher risk profil associ donor heart use oc heart
expand trial trial demonstr short- mid-term surviv rate
day six month respect f/u on-going
addit good rate surviv patient trial experienc sever left
ventricular lv right ventricular rv pgd result present dr
schroeder ishlt sourc
exhibit order primari endpoint oc heart expand surviv expand vs uno nation averag
oc heart expand studi met non-inferior goal data
critic analysi ye concern delta oc arm
nation averag surviv differ explain given
differ criteria donor organ understand transmed
supplement data proceed ii studi expand studi use
pma applic long-term outcom proceed ii also
unclear data expand trial cap arm includ final analysi
fda panel expect eventu although could delay origin timelin
expandoptn componentfreedom pgdcompon outperform
tap dcd heart transplant
white et al frontier cardiovascular medicin feb macdonald et al journal
heart transplant within context donor suffer circulatori death key
reason view excit transmed stori inde mani
issu left sort still point field check key
clinician indic oc system potenti revolution dcd
space dcd space excit potenti expand
avail donor pool also expand durat transport without damag
program need tailor approach focus organ resuscit time
procur ex-situ preserv pre-transpl assess organ viabil
highlight specif work done oc dcd make
follow point contextu discuss view
organ procur pathway dcd complet differ moreov
numer ethic consider harvest organ dcd donor
vari countri countri thu complic protocol standard
heart dcd patient withdraw life support undergo greater
ischem injuri patient therefor addit step requir
make sure heart viabl transplant new concept warm
ischem standoff period brought pictur
precis marker heart viabil least current clear exampl
studi show lactat level good threshold dcd heart
viabil post-transplant howev evid use lactat alon
determin viabil mix best pcwp cvp ci factor mix
perfus time need dcd heart differ heart
moreov perfus condit perfus mix perfus algorithm
invari go differ remain unclear effect
variabl sort
organ viabil assess whether in-vivo ex-vivo remain somewhat art
one fundament differ dcd diagnosi death
base neurolog criteria donor still intact cardiac function
dcd diagnosi death base cessat cardiorespiratori function donat
circulatori death heart experi period warm ischemia progress
circulatori arrest declar death durat import criterion
select heart transplant warm ischemia time wit offici refer
time withdraw life support wlst organ reperfus
refin criteria use function warm ischem time fwit refer time
systol bp decreas mmhg least minut organ
reperfus fwit meant provid accur estim actual
ischem injuri sustain donor organ follow wlst howev insuffici end-
organ deliveri onset organ ischemia may occur signific declin
bp occur
exhibit process heart transplant
tradit approach transplant heart
procur donat brain death donor donor heart
evalu carri donor intact
cardiorespiratori function viabl organ arrest
cardiopleg solut store profoundli hypotherm
state cold-stat storag transplant organ ischemia
limit time procur transplant
 tradit approach transplant util
heart procur donat circulatori death
donor donor progress circulatori arrest follow
withdraw life-sustain therapi wlst ethic
mandat standoff period must observ
circulatori death declar consequ heart
sustain signific warm ischem insult organ
procur proceed subsequ preserv use
cold-stat storag subject heart addit cold
ischem injuri provid opportun organ
resuscit evalu tradit approach
unlik facilit success transplant heart
donat circulatori death
 tailor approach transplant heart
procur donat circulatori death donor
follow wlst declar circulatori death heart
resuscit use approach tailor minim
ischemia-reperfus injuri heart preserv use
ex situ heart perfus minim exposur cold
ischemia facilit organ evalu organ ischemia
limit time wlst organ resuscit
white et al frontier cardiovascular medicin
one fundament concept understand dcd transplant
notion heart undergo ischemia longer durat therefor requir
refin resuscit strategi extub dcd heart forc
function increasingli hypox environ attempt maintain
system deliveri hypoxemia hypercabria caus constrict
pulmonari vasculatur distens rv chang prompt
catecholamin surg transient hyperdynam circulatori phase howev
myocardi energi store rapidli deplet cardiac output declin
donor progress circulatori arrest donor heart remain warm
distend ischem state ethic mandat standoff period
therefor time organ procur dcd heart withstood
exposur surg catecholamin sustain signific ischem insult
cellular level ischem injuri result deplet atp store
anaerob metabol ultim lead intracellular acidosi thu
fundament cornerston dcd heart procur minim wit
dcd heart resuscit procur
differ protocol talk heart procur dcd
direct procur preserv dpp normotherm region
perfus nrp descript simpli meant present bird eye
view dcd organ procur transplant procedur note
excit space built clinic work done papworth
sydney protocol might differ one place anoth henc
care taken analysi result dpp protocol heart
resuscit cardiopleg solut tailor minim ischemia-
reperfus injuri preserv ex-situ normotherm beat state organ
evalu carri ex-situ preserv identifi viabl organ
transplant nrp protocol heart resuscit in-vivo veno-arteri
ecmo in-vivo assess heart function carri viabl
organ procur preserv ex-situ normotherm beat state
transplant supplementari organ evalu carri ex-situ
dpp wide varieti strategi demonstr efficaci mitig
ischemia-reperfus injuri like deliveri cardiopleg solut
contain cocktail complementari pharmacolog post-condit agent
target varieti pathway involv pathogenesi ischem
reperfus injuri improv dcd heart resuscit current protocol
nrp involv reperfus donor blood follow initi veno-arteri
ecmo donor blood time reperfus may benefici properti
would facilit dcd heart resuscit energi substrat buffer
exist donor blood may facilit restor myocardi energi store
regard nrp may serv resuscit dcd heart propon also
believ provid expediti reperfus minim wit
compar dpp potenti downsid nrp may high level
catecholamin pro-inflammatori cytokin present within dcd
donor may detriment effect myocardi resuscit
white et al frontier cardiovascular medicin
normotherm hypotherm heart preserv
normotherm ex-situ heart preserv shown maintain aerob
metabol limit exposur cold ischemia organ preserv also
facilit deliveri pharmaceut recondit dysfunct organ
includ stem cell gene therapi final normotherm preserv
provid opportun perform metabol function assess
preserv interv order identifi organ suitabl
transmed oc prime exampl leukocyte-deplet whole
blood obtain donor organ procur usual
combin proprietari prime solut contain physiolog salt
ciprofloxacin cefazolin perfus mainten solut contain
dextros amino acid adenosin epinephrin titrat achiev desir
aortic perfus pressur coronari blood flow perfus solut
circul oxygen heat exchang coronari
perfus oxygen solut lv preserv unload
beat state therefor assess viabil limit metabol
profil oc util whole-blood base perfus help explain
anti-oxid anti-inflammatori effect presenc albumin
plasma protein blood methylprednisolon thought minim
myocardi edema especi given increas pro-inflammatori
cytokin observ regular preserv interv mannitol
oncot agent presum also help myocardi edema target perfus
pressur oc state mmhg rang pulsatil
waveform reduc myocardi edema final numer studi shown
myocardi function declin linear fashion ex-situ preserv
even normal heart undergo prolong perfus therebi limit safe
preserv time potenti resuscit dysfunct heart limit free
fatti acid deplet replenish myocardi energi store insulin amino acid
glucos thought counter myocardi declin
hypotherm perfus investig altern method
support altern aerob metabol minim dcd heart exposur
cold ischemia preserv interv hypotherm perfus
achiev use simpler less expens perfus apparatu problem
hypotherm perfus though remain assess organ viabil
limit evalu metabol state lactat metabol sinc heart
preserv hypotherm arrest state assess organ function
possibl view remain one critic issu
hypotherm ex-situ perfus preserv
papworth hospit uk set special dcd program heart
transplant base dr messer present ishlt seem
transplant activ papworth increas part due
success program note field check indic dcd
transplant done papworth dont data
highlight abl find
ishlt present sourc
dr messer talk dcd
heart retriev use direct procur perfus oc
normotherm region perfus nrp follow normotherm machin
perfus use oc nrp follow cold static storag
transport outcom consecut dcd heart transplant
patient march march match heart
transplant primari endpoint surviv secondari outcom
includ use mechan inotrop support cardiac perform
mechan ventil durat hospit durat reject episod
studi flowchart shown next exhibit
donor recipi demograph match dcd vs nrp vs dpp
protocol shown next page
dcddbdnrpdppn deathhypox brain injuri hemorrhag brain injuri wood transplant cardiomyopathi cardiomyopathi cardiomyopathi heart diseas heart rv death withdraw ischem time warm ischem time perfus time durat transmed
outcom studi shown next exhibit ninety-day surviv
dcd group vs group similarli surviv
dpp protocol group vs nrp group
exhibit outcom papworth dcd vs heart tx studi
papworth program understand offici result
increas heart transplant respect center also becom
basi us dcd note accord ishlt
mortal heart transplant lead caus death
attribut primari graft failur henc number dcd look
dcd studi done sydney along papworth studi highlight
earlier reason interest transmed stori dcd studi
led increas heart transplant sydney center dcd
heart studi author report heart retriev dcd
donor referr sinc dcd heart male femal donor yr
age accept condit warm ischem time
minut also criteria transplant base combin
lactat profil stabil hemodynam physiolog paramet
oc system serial visual assess downward trend lactat profil
eventu adopt stringent initi criteria mmol/l
dcd retriev chart donor recipi baselin characterist shown
oc machin failur occurredon due clot circuit
second one due faulti electr contact dispos modul
base unit lead pump shutdown heart perfus
intraop tee perform case assess graft function post-
reperfus retrospect review tee report show sever biv
failur seven patient isol lv failur one patient patient
intraop tee report miss none patient proceed
requir postop total seven patient proceed requir
ecmo iabp one case wean bypass patient
requir ecmo support lv failur observ patient
success manag higher dose inotrop support
postop total recipi requir initi ecmo support
wean delay graft function eighth case
heart initi wean return due surgic
bleed around aortic anastomosi result decis ecmo
support second wean ecmo support institut
averag day return normal biv function document
hemodynam monitor tee prior ecmo decannul total eight
patient situ lvad ecmo requir statist higher
lvad explant recipi compar without pre-transpl
result studi shown exhibit overal surviv
dcd cohort month year year
post-transpl four patient pass three year
transplant total follow-up time survivor day
time public one earli mortal recipi day
post-transpl dcd cohort due primari graft failur author point
despit good lvef prior transplant lactat level
mmol/l start within first minut level fallen
remain level next minut
final measur arteri lactat product venou
lactat level measur donor heart
exhibit order kaplan meier curv dcd heart studi compar surviv curvesdbd vs dcd
american journal transplant volume etc
case heart lung liver transplant also sever restrict
given imbal demand suppli us
liver get use patient die wait transplant list uk
exampl shortag donor liver made dcd liver
donor pool transplant made dcd liver
unfortun graft loss recipi mortal dcd liver shown
liver sourc callaghan et al british medic journal volume
world-wide obes epidem result greater number
donor incident hepat steatosi contribut number
margin donor liver steatot liver largest group poorli util
organ resuscit fatti liver import goal whilst combat
grow obes epidem concept pharmacolog intervent
revers steatosi normotherm perfus current explor
sever team around world although unclear whether remov fat
viabl liver normotherm perfus would relev improv
post-transpl function outcom treat organ shown
significantli better metabol paramet compar match control
histolog improv becam appar six hour
interest normotherm organ perfus liver especi dcd therefor
view great interest
mechan action normotherm perfus
standard cold storag remain standard-of-car preserv method
liver transplant aim maintain structur function integr
liver promot function reperfus achiev cool
preserv solut decreas cellular energi consumpt
reduc metabol demand tissu composit
preserv solut aim reduc cell swell lysi associ
cool primari object preserv attenu ischemia/reperfus
injuri iri result efflux accumul metabol product
form ischemia result profound inflammatori immun respons
reperfus caus hepatocellular injuri low-risk liver
adequ preserv method liver abl toler
modest level iri satisfactori post-transpl outcom surviv
rate howev margin liver toler ischemia poorli experienc
sever inflammatori respons reperfus injuri result poor short-term
long-term outcom
normotherm perfus nmp maintain liver ex-vivo fulli function
state provid oxygen nutrient nmp circuit function
principl physiolog preserv maintain cellular metabol
throughout preserv period princip compon includ follow
blood reservoir pump circuit compris two pump portal venou
hepat arteri flow oxygen heat exchang comparison
devic either commerci avail use clinic trial
shown next exhibit nmp superior term synthet
metabol liver function post-transpl surviv shown larg
anim model sourc brockmann et al annal surgeri volume
schon et al annal surgeri volume evid ex-vivo bile
product reduct marker cell injuri post-transpl surviv
howev precis mechan underpin benefici effect nmp
yet fulli elucid like perfus help maintain
healthi endothelium replenish adenosin triphosph atp
import increas hepat atp human liver transplant
shown direct correl high hepat atp content good post-
transplant outcom recent human studi demonstr
histolog evid glycogen replet nmp glycogen essenti
maintain hepatocellular integr function suppli glucos atp
gener glycogen consum atp deplet ensu lead
irrevers cell injuri necrosi
liver usual discard base report donor characterist well
gross appear organ howev lack valid object
predictor function inevit result organ turn would
function transplant well reduc ischem reperfus injuri
promot liver regener potenti perform viabil assess
liver ex-vivo could undoubtedli increas number transplant liver
surgeon make object assess liver function
preserv potenti predict post-transpl outcom highlight
key clinic trial nmp space includ
transmedicss competitor europ one key metric look peak
serum ast aspart aminotransferas first hr
valid surrog marker graft patient surviv
cope multicent rct initi consortium organ preserv
europ involv seven european transplant center adult type
dcd liver randomli assign continu nmp
primari end point differ peak-ast requir transplant
power detect reduct secondari endpoint includ organ
patient surviv ischem cholangiopathi mrcp normotherm
perfus cope trial done use organox metra devic
overal liver nmp enrol consist
dcd organ forty-eight liver discard retriev vs
nmp two other declin transplant non-trial
site nmp liver experienc significantli longer preserv time
vs earli graft function superior nmp
group regard peak ast iu/l vs nmp
ead vs nmp magnitud effect
greater dcd organ anoth notabl find reduc
rate liver discard organ random nmp signific
differ two group versu nmp
exhibit outcom cope trial use organox metra
oc liver protect trial prospect random
control trial evalu safeti effect oc liver system
dcd liver compar arm standard cold storag primari
endpoint includ incid earli liver graft dysfunct
incid liver graft relat sae long-term endpoint includ
patient surviv year trial base clinicaltri gov
complet enrol understand readout expect
happen regulatori approv sometim base
result present markmann et al sourc american journal
transplant volume initi experi oc demonstr
safeti encourag clinic outcom specif result initi
patient trial oc control incid ead patient
oc vs control patient surviv day
lgr sae oc vs lgr sae control liver biopsi
assess demonstr lower ir injuri marker lsec loss oc
arm compar control
oc liver reviv european singl arm trial evalu
safeti perform oc liver preserv assess dcd
donor liver transplant donor inclus criteria age year old
total cross clamp time hour dcd year old macrosteatosi
donor exclus live split donor sever liver injuri recipi inclus
criteria age year regist male femal primari liver transplant
candid sign written inform consent trial recipi exclus
depend time transplant short-term endpoint includ incid
ead within seven day post-transpl patient graft surviv
post-transpl length initi posttranspl icu stay hospit stay
safeti assess incid devic relat loss organ
access interim result reviv present ishlt
present patient transplant total cross clamp time
mt mt perfus time oc
mt donor dcd liver safe perfus
demonstr normal physiolog function oc liver system
produc bile stabl perfus paramet trend lactat
mmol/l mmol/l liver preserv oc system
success transplant incid ead patient day
surviv lgr sae patient graft surviv hospit discharg
day post-transplant icu stay hour total
organox base uk develop metra normotherm perfus
system liver transplant system commerci approv europ
liver tx undergo evalu pivot trial us devic design
shown
paragonix base massachusett develop sherpapak line
cold storag ship contain heart pancrea liver kidney transport
note system involv perfus static storag
organ assist base netherland manufactur rang hypotherm
perfus system liver kidney lung preserv transport
organ recoveri system base illinoi manufactur rang hypotherm
perfus system liver kidney preserv transport
xvivo base netherland manufactur rang normotherm
perfus system lung heart preserv transport
exhibit list ex-vivo perfus system
salehi et al yale journal biolog medicin volume
transmed earli stage life cycl therefor
view within context compani current one approv
indic us lung wait pma approv heart
indic post-panel sometim compani continu heavili
invest clinic trial therefor necessit heavi spend
accordingli taken account regulatori clinic timelin account
clinic spend top-lin growth europ heart lung liver
indic approv contribut heart segment
lung section remain overal revenu
expand compound-annual-growth-rate
exhibit order annual revenu profil contribut variou segment
revenu recognit transmed includ adjust clinic trial
relat cost us heart clinic trial transmed reimburs
hospit portion cost exampl us heart revenu
adjust lead net revenu
transmed note pro-forma estim net
clinic trial current bulk revenu transmed lay
ground work innov service-bas program could help
increas organ transplant per center offload workload
constraint current transplant center shown organ
transplant center oc ultra-concentr nation
transplant center us given high capit outlay
highli stringent criteria organ transplant success laid uno
end transplant center us use oc
lung center use oc heart liver new program
call partnership high-volum opo organ procur
organ countri goal would service-bas contract
transmed would suppli labor logist requir organ
retriev manag organ organ preserv compani
believ current staff constraint transplant center lead
offload ancillari workload transplant center
exampl charg organ retriev organ
preserv organ manag transmed believ
increas organ transplant increas revenues/cas
exhibit distribut oc center us organ type
comprehens analysi margin profil transmed use
stage compani life cycl time believ possibl
compani reach normal gross margin ebit
margin envis occur earliest
mileston hit normal margin come play
us pma approv heart indic launch
dcd heart use continu decent clip uk australia
liver readout us approv
geographi europ
enrol on-going clinic trial usoc liver oc heart
expand cap dcd oc lung registri continu
pro forma model assum continu uptick heart segment us
liver commerci revenu kick sometim time
note due dilig indic new center come on-line requir
purchas dispos kit up-front therefor requir invest henc
actual number implant vs amount dispos kit sold might
lag time note actual number could dwarf estim
time especi center increas number transplants/quart
dcd extend criteria transplant market begin bear fruit
current environ creat temporari paus market
hospit cope huge influx patient ard organ
transplant specif categor postpon
guidelin surgeri deferr issu earli march note prudent
conserv reason pro forma estim
much lower street
exhibit forma quarterli revenu file transmed
dr wale hassanein found transmed revolution organ
transplant therapi treatment end-stag lung heart liver failur dr
hassanein name one top global thinker healthcar
foreign polici magazin awarde tribeca disrupt
innov award finalist european patent offic
inventor award dr hassanein frequent guest speaker nation
intern meet futur organ preserv transplant
dr hassanein earn georgetown univers school medicin
complet two year gener surgeri train georgetown univers
medic center complet three-year cardiac surgeri research
fellowship west roxburi va medic center brigham women
hospit boston research ex-vivo heart perfus transplant
recogn american associ thorac surgeri
stephen gordon join transmed march lead financ
account team year experi lead financi
organ within high technolog medic devic compani prior
join transmed mr gordon vice presid financi plan
analysi analog corpor medic devic secur technolog
posit cytyc maxtor hewlett-packard mr gordon earn
bachelor degre financ account wharton school
univers pennsylvania boston univers
dr khayal join transmed past year dr khayal
assum grow respons current role chief commerci offic
januari chief medic offic lead
transmed global effort build clinic evid reimburs
initi use model integr program support pma approv
global commerci adopt oc technolog lung heart liver
transplant prior join transmed dr khayal serv six year
director medic affair zentiva middl east pharmaceut
compani led clinic research regulatori file clinic sale
train compani oper dr khayal receiv md degre
cairo univers school medicin gener certif educ
univers london england
initi coverag transmed outperform rate
month pt pt repres sale estim
slight premium aggreg med-tech space current trade
forward p/ view transmed oc normotherm perfus
system solid organ transplant disrupt play segment
desper need new technolog solid organ transplant across world
limit limit donor avail inabl util organ
otherwis could transplant limit geograph avail poor
clinic outcom especi organ heart lung liver allow
organ assess preserv abil standard
organ preserv transplant world-wide construct stanc
stori temper realiti number thing dont know
normotherm preserv solid organ oc perform
certain condit report europ exampl replic
us case dcd heart transplant contend oc
could repres paradigm chang organ transplant space henc
rate price target
exhibit forward price/sal vs micro-cap univers
oppenheim co factset estim
clinic risk far biggest risk stori transmed conduct
numer clinic trial variou solid organ preserv transplant suffic
say final outcom depend donor recipi
characterist also transplant techniqu specif follow-up period
execut risk key risk stori compani balanc
requir properli conduct clinic trial new indic label
expans commerci alreadi approv indic
organ transplant market realli seen innov year
normotherm ex-vivo perfus repres paradigm chang suffic
say way clinic trial design current leav room debat henc
like tug war current practic cold storag preserv
transport take time implant use oc make
definit argument clinic benefit normotherm ex-vivo perfus
market risk center continu exist practic
statement oper
good sold
chang fair valu warrant
sg
equival
current portion defer rent
long-term debt net discount current
defer rent net current
accumul comprehens incom loss
stock price compani mention report
